PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW122450View Pathway |
physiological
PathwayHomo sapiens
|
Creator: Guest: Anonymous Created On: April 15, 2019 at 08:17 Last Updated: April 15, 2019 at 08:17 |
PW124347View Pathway |
disease
Pathway in cancerHomo sapiens
|
Creator: Guest: Anonymous Created On: November 19, 2020 at 11:38 Last Updated: November 19, 2020 at 11:38 |
PW000974View Pathway |
PathWhiz Pt.2 - Video Learning Tutorials (Skeleton)Homo sapiens
|
Creator: Guest: Anonymous Created On: July 15, 2015 at 10:00 Last Updated: July 15, 2015 at 10:00 |
PW000954View Pathway |
PathWhiz Pt.2 Learning Tutorials (Membrane)Homo sapiens
|
Creator: Bioinformatics Learning Tutorials Created On: June 23, 2015 at 15:59 Last Updated: June 23, 2015 at 15:59 |
PW000969View Pathway |
PathWhiz Pt.2 Learning Tutorials (Red Membranes)Homo sapiens
|
Creator: Bioinformatics Learning Tutorials Created On: July 03, 2015 at 13:43 Last Updated: July 03, 2015 at 13:43 |
PW000945View Pathway |
PathWhiz Pt.2 Learning Tutorials (Skeleton)Homo sapiens
|
Creator: Bioinformatics Learning Tutorials Created On: June 12, 2015 at 16:50 Last Updated: June 12, 2015 at 16:50 |
PW146056View Pathway |
drug action
Patiromer Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 17:18 Last Updated: October 07, 2023 at 17:18 |
PW126813View Pathway |
drug action
Paxlovid (Drug Action)Homo sapiens
|
Creator: Nitya Khetarpal Created On: April 01, 2022 at 15:33 Last Updated: April 01, 2022 at 15:33 |
PW128514View Pathway |
drug action
Pazopanib Action PathwayHomo sapiens
Pazopanib is an antineoplastic agent utilized for treating advanced renal cell cancer and advanced soft tissue sarcoma in patients who have undergone prior chemotherapy. This small molecule functions as an inhibitor of multiple protein tyrosine kinases, demonstrating potential antineoplastic activity. By targeting vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-alpha, PDGFR-beta), and c-kit, which are integral to the angiogenesis pathway, pazopanib hinders tumor blood vessel formation, ultimately impeding tumor survival and growth. Notably, it achieves steady-state concentrations conducive to maximal inhibition of VEGFR2 phosphorylation and exhibits anti-tumor effects, leading to a reduction in tumor blood flow, increased tumor apoptosis, inhibited growth, and hypoxia in cancer cells. Although absorption is slow and incomplete, with nonlinear tendencies over a dose range of 50-2000 mg, pazopanib's potency in targeting key receptors underscores its significance as a therapeutic option for patients with advanced renal cell cancer and advanced soft tissue sarcoma.
|
Creator: Dorsa Yahya Rayat Created On: September 01, 2023 at 11:50 Last Updated: September 01, 2023 at 11:50 |
PW145718View Pathway |
drug action
Pazopanib Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 16:27 Last Updated: October 07, 2023 at 16:27 |